Wednesday, October 7, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· May 14, 2026

POET Technologies Reports First Quarter 2026 Financial Results

View original at globenewswire.com
“The Company reported a net loss of $12.3 million, or ($0.08) per share, in the first quarter of 2026”
Verbatim excerpt from the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • POET's Optical Interposer-based products are lower cost, consume less power than comparable products, are smaller in size and are readily scalable to high production volumes

    60% confidence
  • In Q1 2026, POET made significant progress expanding its strategic position within the AI and hyperscale data center ecosystem; partnerships with LITEON, Lessengers and Lumilens validate growing demand for POET's Optical Interposer platform

    60% confidence
  • POET continued to advance its product roadmap through joint development of a 1.6T transceiver platform with Lessengers, strengthened global position through LITEON collaboration, and plans US domicile as demand for AI networking infrastructure accelerates

    60% confidence
  • The largest component of Q1 2025 net income was a non-cash gain in fair value adjustment to derivative warrant liability of $15.4 million, compared to a gain of $1.6 million in Q1 2026

    60% confidence
  • The Lumilens purchase order represents the first phase of a broader supplier relationship that could scale to $500+ million in cumulative purchases over five years

    60% confidence
  • Fluctuations in R&D expense for a company of POET's size and stage of growth is expected on a period-over-period basis as the Company transitions from technology development to product development

    60% confidence
  • The Lumilens joint development agreement including the initial $50M purchase order for EOI-based optical engines represents an important commercial milestone and could become a substantial long-term supplier relationship supporting frontier AI infrastructure

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,351 source documents archived
Query this data → isubstrate.com